Improvements in Hematological Parameters and Quality of Life (QOL) with Elritercept (KER-050): Results from an Ongoing Phase 2 Trial in Participants with Lower-Risk (LR) Myelodysplastic Neoplasms (MDS)

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Blood

Topics

Medicine

Cancer Oncology

Internal Medicine

Hematology

Genetics

Show all topics

DOI

10.1182/blood-2024-203274